These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 22382681)
1. Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death. Cho SY; Jeong EM; Lee JH; Kim HJ; Lim J; Kim CW; Shin DM; Jeon JH; Choi K; Kim IG Mol Cells; 2012 Mar; 33(3):235-41. PubMed ID: 22382681 [TBL] [Abstract][Full Text] [Related]
2. Functional characterization of naturally occurring transglutaminase 2 mutants implicated in early-onset type 2 diabetes. Salter NW; Ande SR; Nguyen HK; Nyomba BL; Mishra S J Mol Endocrinol; 2012 Jun; 48(3):203-16. PubMed ID: 22394545 [TBL] [Abstract][Full Text] [Related]
3. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207 [TBL] [Abstract][Full Text] [Related]
4. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756 [TBL] [Abstract][Full Text] [Related]
5. Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. Filiano AJ; Bailey CD; Tucholski J; Gundemir S; Johnson GV FASEB J; 2008 Aug; 22(8):2662-75. PubMed ID: 18375543 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of transglutaminase 2 (TG2) at serine-216 has a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN. Wang Y; Ande SR; Mishra S BMC Cancer; 2012 Jul; 12():277. PubMed ID: 22759359 [TBL] [Abstract][Full Text] [Related]
7. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer. Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935 [TBL] [Abstract][Full Text] [Related]
8. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival. Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875 [TBL] [Abstract][Full Text] [Related]
9. Role of transglutaminase 2 in A Vyas FS; Nelson CP; Dickenson JM Eur J Pharmacol; 2018 Jan; 819():144-160. PubMed ID: 29208472 [TBL] [Abstract][Full Text] [Related]
10. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival. Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691 [TBL] [Abstract][Full Text] [Related]
11. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26. Kotsakis P; Wang Z; Collighan RJ; Griffin M Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178 [TBL] [Abstract][Full Text] [Related]
12. Gα(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells. Obara Y; Yanagihata Y; Abe T; Dafik L; Ishii K; Nakahata N Cell Signal; 2013 Mar; 25(3):589-97. PubMed ID: 23200849 [TBL] [Abstract][Full Text] [Related]
13. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target. Agnihotri N; Mehta K Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794 [TBL] [Abstract][Full Text] [Related]
14. The complex role of transglutaminase 2 in glioblastoma proliferation. Gundemir S; Monteagudo A; Akbar A; Keillor JW; Johnson GVW Neuro Oncol; 2017 Feb; 19(2):208-218. PubMed ID: 27591334 [TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization. Gundemir S; Colak G; Feola J; Blouin R; Johnson GV Biochim Biophys Acta; 2013 Jan; 1833(1):1-10. PubMed ID: 23085038 [TBL] [Abstract][Full Text] [Related]
17. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Liu T; Tee AE; Porro A; Smith SA; Dwarte T; Liu PY; Iraci N; Sekyere E; Haber M; Norris MD; Diolaiti D; Della Valle G; Perini G; Marshall GM Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18682-7. PubMed ID: 18003922 [TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 promotes both caspase-dependent and caspase-independent apoptotic cell death via the calpain/Bax protein signaling pathway. Yoo JO; Lim YC; Kim YM; Ha KS J Biol Chem; 2012 Apr; 287(18):14377-88. PubMed ID: 22418443 [TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice. Sarang Z; Molnár P; Németh T; Gomba S; Kardon T; Melino G; Cotecchia S; Fésüs L; Szondy Z Hepatology; 2005 Sep; 42(3):578-87. PubMed ID: 16108039 [TBL] [Abstract][Full Text] [Related]
20. Tissue transglutaminase-mediated chemoresistance in cancer cells. Verma A; Mehta K Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]